Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report |
Lee, So-Ra
(Department of Internal Medicine, Dankook University College of Medicine)
Kim, Young-Min (Department of Internal Medicine, Dankook University College of Medicine) Jung, Ji-Yun (Department of Internal Medicine, Dankook University College of Medicine) Kim, Hyung-Joon (Department of Internal Medicine, Dankook University College of Medicine) Kim, Doh-Hyung (Department of Internal Medicine, Dankook University College of Medicine) Park, Keon-Woo (Department of Internal Medicine, Dankook University College of Medicine) Lee, Soon-Il (Department of Internal Medicine, Dankook University College of Medicine) |
1 | Shahani R, Kwan KG, Kapoor A. Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC). Drug Healthc Patient Saf 2010;2:85-91. |
2 | Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:835-852. DOI ScienceOn |
3 | Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116:4256-4265. DOI ScienceOn |
4 | White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010;182: 396-403. DOI ScienceOn |
5 | Akata K, Yatera K, Ishimoto H, et al. Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma. Intern Med 2011;50:3013-3017. DOI |
6 | Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94: 1569-1575. DOI ScienceOn |
7 | Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83. DOI |
8 | Coppin C. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics 2010;4:91-101. |
9 | Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008;133: 528-538. DOI ScienceOn |
10 | Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91(Suppl 2):S18-S23. |